07:53 AM EST, 11/25/2024 (MT Newswires) -- Medicenna Therapeutics ( MDNAF ) on Monday said it presented preclinical data on its lead compound MDNA11 at the 2024 Annual Meeting of the Society for Neuro-Oncology (SNO) in Houston over the weekend.

According to the statement, the data provides "compelling" evidence of the combined potential to enhance immune activation with MDNA11 and weaken the tumor microenvironment with bizaxofusp, an immunotoxin, to treat "cold tumors" such as glioblastoma (GBM).

"These results are particularly exciting because they demonstrate, for the first time, the synergistic potential of combining MDNA11's ability to reinvigorate the cancer fighting immune system with bizaxofusp's capacity to dismantle the protective tumor microenvironment associated with the most formidable and devastating cancers such as GBM," said President and CEO Fahar Merchant.